Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000260296

Medchemexpress LLC Methyl 8-(tert-butyl)-6-chloroimidazo[1,2-b]pyridazine-2-carboxylate | 1690176-75-0 | MFCD28144723 | 99.8% | C12H14ClN3O2 | 10MG
SDP

Catalog No. 5000260296
Encompass_Preferred

PAR-2-IN-1 is a small-molecule inhibitor of protease-activated receptor 2 (PAR2) signaling with reported anti-inflammatory and anticancer effects. The compound is supplied as a solid research reagent with defined solubility in DMSO and formulation examples for in vivo studies.

  • Selective PAR2 pathway inhibitor.
  • Demonstrated anti-inflammatory and anticancer activity in preclinical studies.
  • High purity (99.8%).
  • Soluble in DMSO (~83.33 mg/mL) and formulatable for in vivo use.
  • Supplied as a stable powder with recommended storage at -20°C.
  • Available in multiple research quantities.

Catalog No. 50-002-60296 Supplier Medchemexpress LLC Supplier No. HY13855810MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

PAR-2-IN-1 is a small-molecule inhibitor of protease-activated receptor 2 (PAR2) signaling with reported anti-inflammatory and anticancer effects. The compound is supplied as a solid research reagent with defined solubility in DMSO and formulation examples for in vivo studies.

  • Selective PAR2 pathway inhibitor.
  • Demonstrated anti-inflammatory and anticancer activity in preclinical studies.
  • High purity (99.8%).
  • Soluble in DMSO (~83.33 mg/mL) and formulatable for in vivo use.
  • Supplied as a stable powder with recommended storage at -20°C.
  • Available in multiple research quantities.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.